Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Download PDF Copy

Dec 22 2014

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN^® for the treatment of pancreatic and ovarian cancers.

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson, President and CEO of Oncolytics. "The EMA serves all 28 member countries of the EU and securing Orphan Designation would help support the future development of REOLYSIN^® in the region."

Source:

Oncolytics Biotech Inc.

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Study brings hope for a more personalized approach to treat ER+ breast cancer

Most Americans unaware that early prostate cancer shows no symptoms

Dormant tumor cells targeted to reduce breast cancer relapse

New drug dismantles cancer cell powerhouse to halt tumor growth

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

Plant-derived carotenoid found to boost immune response against cancer

Study finds minimal risk of second cancer in breast cancer survivors

High protein diet linked to increased risk of cancer-associated venous thromboembolism

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.